We Provide In-Depth Single-Molecule Proteomics Analysis

Whole protein quantification

Detection of low abundant molecules

Nanopore sensors have single-molecule sensitivity which is about 1 million times better than the current gold standard mass spectrometry (MS). Statistical analysis over time (which is accellerated by nanopore multiplexing) allows for absolute and relative quantification of low abundant proteins which is achieved with chemically functionalized serial nanopores.

Post-translational modifications

Site-specific whole protein analysis

90% of FDA approved drugs target a protein but understanding drugs-protein interactions is time consuming, expensive, and often inconclusive. The reason is often too little knowledge about site-specific post-translational modifications. We can measure site-specific glycosylation or phosphorylation and help to draw conclusions from drug-protein interactions.

Protein sequencing

Site-specific analysis of single amino acids

We are currently improving our sensor to site-specifically detect all amino acids in the backbone of proteins and therefore be the first technology allowing for whole protein sequencing.

A Wide Range of Applications in Different Sectors

Pharma

Drug development

Quantify single molecules measure site-specific posttranslational modifications like O-link glycosylation or phosphorylation of antibodies and other proteins. Use our technology to improve and speed up pharmaceutical R&D and identify patient groups in clinical trials based on proteomics.

Biotech

Cell line development

More detailed, faster, and cheaper bioprocess development of cell lines and improved protein quality control.

Academia

High impact research

Customizable interface nanopore sensor with dynamic, serial, parallel, and chemically modified nanopores for new possibilities in single-molecule and single-cell analysis.

Food production

Contamination analysis

Greater food security and improved medical nutrition detecting potentially life threatening low-abundant proteins such as allergenes.

Agriculture

Plant engineering

Increased yield and adoption to climate change.

Space

Extraterrestrial discoveries

Detection of extraterrestrial and unknown molecules. Control of (water) recycling and astronaut health.

The Technology Behind Serial Interface Nanopores

Dynamic: Compared to other nanopore systems with static nanopore sizes, we developed a nanopore sensor with on-demand adjustable pore size in the sub-nanometer range that can be perfectly tailored to measure single-amino acids or large glycans within the same pore.

Specific: Our pores can be functionalized with target specific binders (e.g. aptamers) in order to measure low abundant proteins without full sequencing or fingerprinting to achieve controlled translocation speeds needed for protein sequencing.

Serial: We integrate several pores in series which allows us to measure a single molecule >20 times and thereby reduce the error rate and extract orders of magnitude more information than current nanopore systems.

Scientific Background

The Potential of Single-Molecule Protein Analysis

Proteomics-based technologies have the potential to be truly game-changing in the biomedical field. By improving our diagnostic capabilities through the identification of disease-specific proteins, proteomics-based diagnostics can lead to earlier intervention and more effective treatment. This personalized approach to treatment can lead to better outcomes, improving the overall quality of life for patients. Additionally, proteomics can facilitate drug development by identifying new drug targets and improving the efficacy of existing treatments. Understanding the underlying molecular mechanisms of diseases through the analysis of the entire proteome can lead to the development of more effective and completely new treatments. With continued development and investment, proteomics-based technologies have the potential to revolutionize modern medicine, ultimately improving the lives of millions of people worldwide.

Peer-Reviewed Journal Articles About Our Technology

Further Reading from Literature on Single-Molecule Proteomics

We Are a Team of Experts

We are driven by our vision to improve medical research and thereby help millions of patients.
We strongly believe that our advanced technology can disrupt medical research by unlocking the power of the proteome.

Founders

Dr. Til Schlotter

Co-founder & CEO

MSc./BSc. Mech. Engineering (ETH)

Dr. Julia Wagner

Co-founder & COO

MSc./BSc. Mathematics (TU Vienna, UCL)

Julian Hengsteler

Co-founder & CTO

MSc./BSc. Elec. Engineering (ETH)

Advisors

Prof. Dr. Janos Vörös

Head of LBB (ETH)
Awardee of the Dandelion Award 2022 promoting entrepreneurship at ETH

Prof. Dr. Nako Nakatsuka

Head of CHEMINA (EPFL)
Winner of the MIT Innovator Under 35

Prof. Dr. Tomaso Zambelli

PI at LBB (ETH)

Anil Sethi

Innosuisse coach, entrepreneur (>100 mUS$ raised) in residence ETH